Opening book details…
Can I read Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial on EtoBox?
Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial by Javed Butler; Kevin J. Anstrom; G. Michael Felker; Michael M. Givertz; Andreas P. Kalogeropoulos; Marvin A. Konstam; Douglas L. Mann; Kenneth B. Margulies; Steven E. McNulty; Robert J. Mentz; Margaret M. Redfield; W. H. Wilson Tang; David J. Whellan; Monica Shah; Patrice Desvigne-Nickens; Adrian F. Hernandez; Eugene Braunwald; for the National Heart Lung and Blood Institute Heart Failure Clinical Research Network is a Medicine article available to read on EtoBox.
What is Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial about?
## Importance: Persistent congestion is associated with worse outcomes in acute heart failure (ahf). mineralocorticoid receptor antagonists administered at high doses may relieve congestion, overcome diuretic resistance, and mitigate the effects of adverse neurohormonal activation in ahf. ## Objective: To assess the effect of high-dose spironolactone and usual care on n-terminal pro-b-type natriuretic peptide (nt-probnp) levels compared with usual care alone. ## Design, setting, and participants: This double-blind and placebo (or low-dose)-controlled randomized clinical trial was conducted in 22 us acute care hospitals among patients with ahf who were previously receiving no or low-dose (12.5 mg or 25 mg daily) spironolactone and had nt-probnp levels of 1000 pg/ml or more or b-type natriuretic peptide levels of 250 pg/ml or more, regardless of ejection fraction. ## Interventions: High-dose spironolactone (100 mg) vs placebo or 25 mg spironolactone (usual care) daily for 96 hours. ## Main outcomes and measures: The primary end point was the change in nt-probnp levels from baseline to 96 hours. secondary end points included the clinical congestion score, dyspnea assessment, net urine
Who reads Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Javed Butler; Kevin J. Anstrom; G. Michael Felker; Michael M. Givertz; Andreas P. Kalogeropoulos; Marvin A. Konstam; Douglas L. Mann; Kenneth B. Margulies; Steven E. McNulty; Robert J. Mentz; Margaret M. Redfield; W. H. Wilson Tang; David J. Whellan; Monica Shah; Patrice Desvigne-Nickens; Adrian F. Hernandez; Eugene Braunwald; for the National Heart Lung and Blood Institute Heart Failure Clinical Research Network
- Publisher
- American Medical Association (AMA)
- Published
- 2017
- Language
- EN
- Field
- Medicine (Health Sciences)